Teacher Retirement System of Texas Raises Stake in Hologic, Inc. (NASDAQ:HOLX)

Teacher Retirement System of Texas boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 82.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 649,883 shares of the medical equipment provider's stock after buying an additional 294,538 shares during the period. Teacher Retirement System of Texas owned approximately 0.29% of Hologic worth $46,850,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. First Horizon Advisors Inc. grew its holdings in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after purchasing an additional 134 shares in the last quarter. Brooklyn Investment Group grew its stake in Hologic by 14.7% in the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider's stock worth $82,000 after buying an additional 145 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares during the last quarter. Trivant Custom Portfolio Group LLC raised its position in shares of Hologic by 2.1% during the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider's stock valued at $602,000 after buying an additional 169 shares in the last quarter. Finally, Loomis Sayles & Co. L P lifted its holdings in shares of Hologic by 29.3% during the 3rd quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider's stock worth $66,000 after acquiring an additional 183 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Ratings Changes

Several analysts recently weighed in on HOLX shares. Stephens reiterated an "overweight" rating and issued a $84.00 price target on shares of Hologic in a report on Thursday, February 6th. Evercore ISI reduced their target price on Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a report on Thursday, February 6th. Needham & Company LLC cut Hologic from a "buy" rating to a "hold" rating and set a $90.00 target price for the company. in a research note on Monday, February 3rd. Leerink Partnrs cut Hologic from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Finally, Raymond James reissued an "outperform" rating and set a $90.00 price objective (down previously from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $84.62.

Hologic Stock Performance

HOLX stock traded down $1.09 during trading on Tuesday, reaching $60.80. The stock had a trading volume of 2,378,048 shares, compared to its average volume of 1,754,307. The firm has a market cap of $13.64 billion, a PE ratio of 19.18, a PEG ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The stock's 50 day moving average is $65.89 and its two-hundred day moving average is $73.81. Hologic, Inc. has a 52 week low of $60.34 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.